Life science deal good news for patients
More patient friendly drug delivery methods are being accelerated following the acquisition by solutions provider Intertek of Cambridge-based Melbourn Scientific. The value of the all-UK medical technology deal is not being disclosed.
Intertek says the deal will significantly enhance delivery of better, less invasive treatments for patients affected by a range of diseases as capabilities are combined. Both companies work for global clients in the life sciences segment.
Melbourn has over 20 years of experience in analytical testing and formulation for inhaled products and its reputation for providing outstanding and responsive customer service, along with its specialist skills, complement Intertek’s existing technical capabilities and culture.
Intertek has a network of more than 1,000 laboratories and offices and over 35,000 people in more than 100 countries.
Melbourn’s business employs 80 staff. It’s 20,000 sq ft facility is Good Manufacturing Practice (GMP) compliant, regularly inspected by the UK Medicines and Health Regulatory Authority (MHRA) and the FDA.
The company’s reputation for providing outstanding and responsive customer service along with its specialist skills have fostered loyal customer relationships of which Melbourn is especially proud and which complements Intertek’s existing technical capabilities and culture.
Moving from injection to oral inhalation, for example, is a key strategy of many global pharmaceutical majors to achieve increased market share by improving bioavailability and drug use uptake within a patient population (by improving delivery at the true target) whilst reducing patient trauma.
Dr Andrew Swift, SVP, Intertek Chemicals and Pharmaceuticals, said: “Combining Intertek’s GMP/GLP pharmaceutical/biopharmaceutical studiesand our advanced capabilities for measuring device/drug interactionwith Melbourn’s expertise in OINDP drug characterisation provides a unique and compelling offering to clients.
“Adding in our global reach and regulatory services, Intertek now offers a comprehensive and global end-to-end expert service to support drug development which is unmatched by current competitors.
Mark Hammond, CEO, Melbourn Scientific, added: “Now Melbourn is under the umbrella of Intertek it will allow us to offer a wider range of services to our existing customers as well as introduce our specialist expertise to Intertek’s impressive network of clients. The move will also greatly enhance the career development and progression opportunities for our staff.”
• PHOTOGRAPH SHOWS: Mark Hammond